Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02930824 · ClinicalTrials.gov registry record · NA
Genotype-supported Versus Conventional Proton Pump Inhibitor Dosing
A NA study, sponsored by University of Florida.
- Completed
- Registry status
- NA
- Development phase
- 185
- Enrollment target
NCT02930824: Completed NA study, sponsored by University of Florida.
NCT02930824 is a NA study that has completed, run by University of Florida. The registered enrollment target is 185 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (87% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02930824, a NA study, has completed, sponsored by University of Florida.
- COMPLETED
- Registry status
- NA
- Development phase
- 185 participants
- Enrollment target
Study Summary
Investigators will conduct a comparative effectiveness study of genotype-supported vs. conventional PPI dosing. Adults and children presenting with Gastroesophageal Reflux Disease (GERD) or dyspepsia symptoms and either 1) being initiated on proton pump inhibitor (PPI) therapy or 2) with continued symptoms on current PPI therapy will be recruited from gastroenterology clinics and randomized to a genotype-supported versus conventional PPI therapy management strategy.
Primary Outcome
The RDQ was developed to monitor treatment response over time and evaluates 6 symptoms (12 items) covering 3 domains: heartburn, regurgitation, and upper abdominal pain. Each symptom is evaluated using a 6-point Likert scale to assess frequency and severity over the previous week. Each symptom is rated from 1 (did not have) to 6 (severe), and the RDQ mean score is calculated as the mean response to the 12 items. The RDQ mean score thus ranges from 1 to 6 and has been psycho-metrically validated.
Interventions
- GENETIC CYP2C19 genotyping
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 185 participants |
| Start Date | 2016-12 |
| Est. Completion | 2019-07-17 |
| Phase | NA |
What the finished NCT02930824 record still lists
NCT02930824 is an interventional study that assigns participants to a tested intervention. The registered 185 participants enrollment target is mid-sized for trials with a published cap, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (87% lower).
The record links to 0 conditions, and to 1 intervention - of which CYP2C19 genotyping is the first listed.
NCT02930824 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02930824 about?
NCT02930824 is a clinical study titled "Genotype-supported Versus Conventional Proton Pump Inhibitor Dosing". Investigators will conduct a comparative effectiveness study of genotype-supported vs. conventional PPI dosing. Adults and children presenting with Gastroesophageal Reflux Disease (GERD) or dyspepsia symptoms and either 1) being initiated on proton pump inhibitor (PPI) therapy or 2) with continued s...
What is the current status of trial NCT02930824?
This trial is currently completed. It is a NA study. The enrollment target is 185 participants. The study started on 2016-12. Estimated completion is 2019-07-17.
What interventions are being tested in trial NCT02930824?
The interventions under investigation include: CYP2C19 genotyping (GENETIC).
Who is sponsoring clinical trial NCT02930824?
This trial is sponsored by University of Florida, which has 1,106 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02930824's enrollment target sits among peer trials
185 580th of 2000 higher than 1,420 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04041154 · 185 participants · NA
Behavioral and Neural Representations of Subjective Effort Cost
- NCT04484272 · 185 participants · NA
A Stress and Pain Self-management m-Health App for Adult Outpatients With Sickle Cell Disease
- NCT05020860 · 185 participants · Phase 2
Correlation of Clinical Response to Pathologic Response in Patients With Early Breast Cancer
- NCT05793541 · 185 participants · NA
Just-in-time Interventions for Reducing Short-term Suicide Risk
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia